These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36873753)

  • 1. Prasugrel-Based De-Escalation in Patients With Acute Coronary Syndrome According to Renal Function.
    Yun JP; Kang J; Park KW; Park K; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Chae IH; Moon KW; Park HW; Won KB; Jeon DW; Han KR; Choi SW; Ryu JK; Jeong MH; Kim HS
    JACC Asia; 2023 Feb; 3(1):51-61. PubMed ID: 36873753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial.
    Hwang D; Lim YH; Park KW; Chun KJ; Han JK; Yang HM; Kang HJ; Koo BK; Kang J; Cho YK; Hong SJ; Kim S; Jo SH; Kim YH; Kim W; Lee SY; Kim YD; Oh SK; Lee JH; Kim HS;
    JAMA Cardiol; 2022 Apr; 7(4):418-426. PubMed ID: 35262625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
    Lee KS; Park KH; Park KW; Rha SW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Lee NH; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Kim SY; Shin WY; Lim HS; Park K; Kim HS
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):262-270. PubMed ID: 36715152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
    Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
    Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI.
    Ki YJ; Lee BK; Park KW; Bae JW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Kim DB; Chae IH; Moon KW; Park HW; Won KB; Jeon DW; Han KR; Choi SW; Ryu JK; Jeong MH; Cha KS; Kim HS;
    Korean Circ J; 2022 Apr; 52(4):304-319. PubMed ID: 35129316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.
    Wöhrle J; Seeger J; Lahu S; Mayer K; Bernlochner I; Gewalt S; Menichelli M; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Kufner S; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Ndrepepa G
    JACC Cardiovasc Interv; 2021 Sep; 14(17):1857-1866. PubMed ID: 34446390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.
    Lee JM; Jung JH; Park KW; Shin ES; Oh SK; Bae JW; Rhew JY; Lee N; Kim DB; Kim U; Han JK; Lee SE; Yang HM; Kang HJ; Koo BK; Kim S; Cho YK; Shin WY; Lim YH; Rha SW; Kim SY; Lee SY; Kim YD; Chae IH; Cha KS; Kim HS
    Trials; 2015 Sep; 16():409. PubMed ID: 26374625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
    Sibbing D; Gross L; Trenk D; Jacobshagen C; Geisler T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Parma R; Felix SB; Neumann FJ; Hausleiter J; Baylacher M; Koltowski L; Mehilli J; Huber K; Huczek Z; Aradi D; Massberg S;
    Eur Heart J; 2018 Aug; 39(29):2749-2758. PubMed ID: 29912422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial.
    Koltowski L; Tomaniak M; Gross L; Rymuza B; Kowara M; Parma R; Komosa A; Klopotowski M; Jacobshagen C; Gori T; Aradi D; Huber K; Hadamitzky M; Massberg S; Lesiak M; Filipiak KJ; Witkowski A; Opolski G; Huczek Z; Sibbing D
    J Thromb Thrombolysis; 2019 Apr; 47(3):427-435. PubMed ID: 30739305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention.
    Koshy AN; Giustino G; Sartori S; Kyaw H; Yadav M; Zhang Z; Hooda A; Farooq A; Krishnamoorthy P; Sweeny JM; Khera S; Serrao GW; Sharma R; Suleman J; Dangas G; Kini AS; Mehran R; Sharma SK
    JACC Cardiovasc Interv; 2022 Nov; 15(22):2270-2280. PubMed ID: 36423970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial.
    Orban M; Trenk D; Geisler T; Rieber J; Hadamitzky M; Gross L; Orban M; Kupka D; Baylacher M; Müller S; Huber K; Koltowski L; Huczek Z; Heyn J; Jacobshagen C; Aradi D; Massberg S; Sibbing D; Hein R;
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):372-381. PubMed ID: 31855244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.
    Coughlan JJ; Aytekin A; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Gewalt S; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Müller A; Kufner S; Liebetrau C; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Fusaro M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A
    JAMA Cardiol; 2021 Oct; 6(10):1121-1129. PubMed ID: 34190967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Ischemic and Bleeding Events According to Renal Function in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Third-Generation Antiplatelet Drugs.
    Ndrepepa G; Lahu S; Aytekin A; Scalamogna M; Coughlan JJ; Gewalt S; Pellegrini C; Mayer K; Kastrati A
    Am J Cardiol; 2022 Aug; 176():15-23. PubMed ID: 35606172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention.
    Davlouros P; Xanthopoulou I; Goudevenos J; Hamilos M; Vavuranakis E; Sitafidis G; Kanakakis I; Deftereos S; Alexopoulos D
    Cardiology; 2017; 138(3):186-194. PubMed ID: 28750372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.